Dry Eyes Treatment in Ranchi
Chronic dry eye is more than discomfort — it is an inflammatory disease of the ocular surface that can damage the cornea and degrade vision. Dr. Dibya Prabha (MS Ophthalmology, FICO, Retina Fellow LV Prasad Eye Institute Hyderabad) provides comprehensive dry eye evaluation and personalized, evidence-based treatment at Neurovision Clinic, Ranchi.
When to Worry
- !Dry eye with significant corneal staining (punctate epithelial erosions involving the central cornea on fluorescein examination) — this indicates that the ocular surface inflammation is severe enough to damage the corneal epithelium. Central corneal involvement degrades vision and, if untreated, can progress to corneal ulceration, filamentary keratitis (strands of degenerated epithelial cells and mucus adherent to the cornea — intensely painful), and bacterial keratitis. These require aggressive lubrication and anti-inflammatory therapy, and in severe cases, amniotic membrane grafting or tarsorrhaphy.
- !Severe dry eye with a history of autoimmune disease — Sjogren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, and other autoimmune conditions are strongly associated with severe aqueous-deficient dry eye. Sjogren's syndrome in particular causes progressive lymphocytic infiltration of the lacrimal and salivary glands, leading to severe dry eye and dry mouth, with a 15 to 20 times increased risk of non-Hodgkin lymphoma. These patients need systemic evaluation by a rheumatologist in addition to intensive ocular surface management by Dr. Prabha.
- !Dry eye that does not respond to standard therapy, or dry eye with associated dry mouth, joint pain, or skin changes — this suggests an underlying systemic condition such as Sjogren's syndrome, graft-versus-host disease (after bone marrow transplant), ocular cicatricial pemphigoid (a scarring autoimmune disease causing severe dry eye, symblepharon, and conjunctival shrinkage), or Stevens-Johnson syndrome. These conditions require coordinated multidisciplinary care and aggressive ocular surface management.
- !Pain out of proportion to clinical signs — if a patient reports severe eye pain but the slit lamp examination shows minimal staining and a relatively normal-appearing ocular surface, this may indicate neuropathic ocular pain (corneal neuralgia). In this condition, the corneal nerves are damaged (from prior LASIK, infection, or chronic dry eye inflammation) and fire aberrantly, causing chronic, severe pain. This is a difficult-to-treat condition requiring neuropathic pain medications (gabapentinoids, tricyclic antidepressants), autologous serum tears, and corneal neurostimulation in select cases. Dr. Prabha recognizes this distinct entity and tailors treatment accordingly.
- !Contact lens wearers with dry eye symptoms — dry eye is the most common reason for contact lens discontinuation. The combination of contact lens and dry eye increases the risk of microbial keratitis (especially if using tap water to rinse lenses or wearing lenses overnight). Contact lens wearers with dry eye symptoms need a comprehensive dry eye evaluation, optimization of the ocular surface, refitting with newer-generation lens materials (silicone hydrogel or scleral lenses for severe dry eye), and reinforcement of lens hygiene. Never ignore dry eye symptoms in a contact lens wearer.
- !Sudden worsening of dry eye symptoms with onset of mouth dryness, difficulty swallowing dry food, or swollen salivary glands — this strongly suggests new-onset or worsening Sjogren's syndrome. In addition to ophthalmological management, referral to rheumatology for systemic evaluation, autoantibody testing (anti-SSA/Ro, anti-SSB/La, ANA, rheumatoid factor), and consideration of systemic immunosuppression is indicated.
Possible Causes
Meibomian Gland Dysfunction (Evaporative Dry Eye)
MGD is the most common cause of dry eye, present in up to 86 percent of cases. The meibomian glands — approximately 30 to 40 in the upper eyelid and 20 to 30 in the lower eyelid — secrete meibum, a complex mixture of lipids (cholesterol esters, wax esters, phospholipids) that forms the outermost layer of the tear film. This lipid layer reduces tear evaporation by approximately 90 percent. In MGD, the gland ducts become obstructed by hyperkeratinized epithelial cells and thickened, solidified meibum. The stagnant meibum becomes chemically altered (increased melting point, release of inflammatory free fatty acids and diglycerides), causing further obstruction, bacterial overgrowth, and inflammation — a vicious cycle. Eventually, the glands undergo atrophy (dropout) — visible on meibography as loss of gland tissue — which is irreversible. Risk factors include: aging, prolonged screen use (reduced blink rate decreases meibum expression), contact lens wear, eyelid inflammation (blepharitis), rosacea, and hormonal changes (androgen deficiency). Treatment targets each component: warm compresses to melt solidified meibum, lid massage to express glands, omega-3 supplements to improve meibum quality, and in-office procedures (thermal pulsation, IPL) for moderate to severe MGD.
Aqueous-Deficient Dry Eye (Lacrimal Gland Dysfunction)
In aqueous-deficient dry eye, the lacrimal glands fail to produce sufficient aqueous tears despite normal evaporative control. The most important cause is Sjogren's syndrome — an autoimmune exocrinopathy where CD4+ T lymphocytes infiltrate and destroy the lacrimal and salivary glands. Primary Sjogren's occurs in isolation, while secondary Sjogren's accompanies another autoimmune disease (most commonly rheumatoid arthritis or systemic lupus erythematosus). Non-Sjogren's aqueous deficiency can result from: aging (lacrimal gland fibrosis and atrophy — the most common cause in older adults), hormonal changes (androgen deficiency in menopause — androgens are trophic to the lacrimal gland), medications (antihistamines, antidepressants with anticholinergic effects, diuretics, beta-blockers, oral contraceptives), chronic contact lens wear (corneal desensitization reduces the neural drive to the lacrimal gland), and damage to the lacrimal gland or its nerve supply (from surgery, trauma, or radiation). Schirmer's test and tear osmolarity help quantify the severity.
Environmental and Occupational Dry Eye
Environmental factors are major contributors to dry eye, particularly in urban and occupational settings. Air-conditioned offices and homes reduce ambient humidity, accelerating tear evaporation. Direct airflow from fans, AC vents, or car heaters onto the eyes is a common and easily modifiable trigger. Prolonged screen use reduces the blink rate from approximately 15 to 20 blinks per minute to as low as 5 to 7, causing tear film stagnation, meibomian gland stasis, and increased evaporative loss. Outdoor occupations with exposure to wind, dust, and sunlight also contribute. Air pollution — particulate matter (PM2.5 and PM10) and ozone — causes oxidative stress and inflammation on the ocular surface. At high altitudes, low humidity and increased UV exposure exacerbate dry eye. These environmental contributors are often additive, and identifying and modifying them is an essential part of Dr. Prabha's management plan — often producing significant improvement without medications.
Medication-Induced Dry Eye
Numerous systemic and topical medications cause or exacerbate dry eye, and a thorough medication review is part of every dry eye evaluation. Common culprits include: systemic antihistamines (cetirizine, loratadine) and first-generation antihistamines (diphenhydramine) which have anticholinergic effects reducing tear secretion; tricyclic antidepressants (amitriptyline, nortriptyline) and SSRIs (fluoxetine, sertraline); diuretics (hydrochlorothiazide, furosemide); beta-blockers (both oral for hypertension and topical for glaucoma — timolol, betaxolol); oral contraceptives and hormonal therapy (estrogen may paradoxically worsen dry eye and meibomian gland function); isotretinoin and other retinoids (potent suppressors of meibomian gland function — dose-dependent atrophy of meibomian glands); benzodiazepines and sleep aids; and anticholinergic medications for overactive bladder (oxybutynin, solifenacin). Topical glaucoma medications, especially those preserved with benzalkonium chloride (BAK), are toxic to the corneal epithelium and cause or worsen dry eye in a significant proportion of chronic users. When medication-induced dry eye is identified, Dr. Prabha works with the patient and their prescribing physician to consider dose reduction, alternative medications with fewer ocular side effects, or preservative-free formulations.
Which Specialist Should You See?
An ophthalmologist is the appropriate specialist for chronic dry eye. Dr. Dibya Prabha (MS Ophthalmology, FICO, Retina Fellow LV Prasad Eye Institute Hyderabad) at Neurovision Clinic, Ranchi, provides comprehensive dry eye evaluation including slit lamp examination, vital dye staining, tear film break-up time, Schirmer's testing, meibomian gland assessment, and when needed, meibography and tear osmolarity. She differentiates the specific dry eye subtype(s) affecting you and creates a personalized, evidence-based treatment plan. For dry eye associated with autoimmune disease, Dr. Prabha coordinates care with rheumatologists and other specialists.
Diagnostic Approach
Dr. Dibya Prabha's dry eye evaluation begins with the Ocular Surface Disease Index (OSDI) — a validated questionnaire that quantifies symptom severity and impact on daily life. A detailed history explores: symptom character and diurnal variation, exacerbating factors (screens, AC, wind, reading), contact lens wear, medication review, medical history (autoimmune disease, rosacea, thyroid disease), and prior dry eye treatments and their effectiveness. The slit lamp examination systematically assesses: eyelid margins (for telangiectasia, collarettes, and meibomian gland orifice obstruction — signs of blepharitis and MGD), meibum quality and expressibility (graded from clear liquid to inspissated toothpaste-like), tear meniscus height (low in aqueous deficiency), conjunctival staining with lissamine green, corneal staining with fluorescein, tear film break-up time, and Schirmer's test when indicated. Meibography (infrared imaging of meibomian glands through the everted eyelid) documents gland dropout and architecture. Tear osmolarity, when available, provides an objective global marker of dry eye severity. Dr. Prabha synthesizes these findings into a subtype diagnosis (aqueous-deficient, evaporative, or mixed) with severity grading, and tailors the treatment plan accordingly.
Experiencing Dry Eyes?
Don't ignore your symptoms. Get expert evaluation from Dr. Dibya Prabha at Neurovision Clinic, Ranchi.
Frequently Asked Questions
What is dry eye syndrome and what causes it?
Dry eye syndrome is a multifactorial disease of the ocular surface characterized by loss of tear film homeostasis, tear hyperosmolarity, ocular surface inflammation, and neurosensory abnormalities. It is not simply a lack of tears — it is a complex disorder where a vicious cycle of tear film instability, hyperosmolarity, and inflammation perpetuates and worsens itself. The Tear Film and Ocular Surface Society (TFOS) DEWS II report classifies dry eye into two main subtypes that often coexist: (1) Aqueous-deficient dry eye — the lacrimal glands fail to produce enough aqueous tears, seen in Sjogren's syndrome (an autoimmune disease where lymphocytes infiltrate and destroy lacrimal and salivary glands, causing severe dry eye and dry mouth), other autoimmune conditions (rheumatoid arthritis, lupus), aging, hormonal changes (especially menopause — androgen deficiency reduces lacrimal gland function), and medications (antihistamines, antidepressants, diuretics, beta-blockers, oral contraceptives, and isotretinoin). (2) Evaporative dry eye — the most common form (present in up to 86 percent of dry eye patients), caused by meibomian gland dysfunction (MGD). The meibomian glands in the eyelids produce the lipid (oil) layer of the tear film that prevents evaporation. When these glands become obstructed or atrophic, the lipid layer is deficient, and tears evaporate too quickly, even if aqueous production is normal. MGD is strongly associated with prolonged screen use (reduced blink rate leads to gland stagnation), contact lens wear, blepharitis, rosacea, and aging. At Neurovision Clinic, Dr. Prabha determines which subtype(s) are contributing to your dry eye so treatment targets the root cause, not just the symptoms.
What are the symptoms of dry eye and how is it diagnosed at Neurovision Clinic?
The symptoms of dry eye are diverse and include: burning or stinging sensation, grittiness or foreign body sensation (feeling like sand in the eyes), paradoxical reflex tearing (the ocular surface irritation triggers a flood of poor-quality tears that overflow but do not coat the eye properly), fluctuating blurred vision that clears with blinking (because the tear film is unstable and breaks up between blinks), redness, photophobia (light sensitivity), stringy mucus discharge, and contact lens intolerance. Symptoms typically worsen as the day progresses, with prolonged screen use or reading, in air-conditioned or windy environments, and in dry climates. Paradoxically, some patients with severe dry eye may have relatively few symptoms because corneal nerve damage reduces sensation. Dr. Dibya Prabha's diagnostic evaluation includes: (1) Slit lamp examination with fluorescein and lissamine green staining — fluorescein reveals areas of corneal epithelial damage (punctate epithelial erosions, filamentary keratitis), while lissamine green stains devitalized conjunctival cells. (2) Tear film break-up time (TBUT) — the time between a complete blink and the first appearance of a dry spot on the cornea. A TBUT of less than 5 to 10 seconds indicates tear film instability. (3) Schirmer's test — a strip of filter paper is placed in the lower eyelid for 5 minutes to measure aqueous tear production; less than 10 mm of wetting indicates aqueous deficiency. (4) Meibomian gland evaluation — the eyelids are examined for gland orifice obstruction, expressibility and quality of meibum (the oil secreted), and gland dropout (atrophy) which can be documented with meibography. (5) Tear osmolarity — elevated osmolarity (greater than 308 mOsm/L or inter-eye difference greater than 8 mOsm/L) is a global marker of dry eye severity. This comprehensive assessment allows Dr. Prabha to classify the type and severity of dry eye and tailor treatment accordingly.
What are the treatment options for dry eye?
Dr. Dibya Prabha follows the TFOS DEWS II stepwise treatment approach, escalating therapy based on severity and type. Step 1 (Mild): Education about the condition, environmental modifications (avoiding direct AC or fan airflow on the eyes, using a humidifier in dry rooms, taking screen breaks using the 20-20-20 rule), and preservative-free artificial tears tailored to the type of dry eye — lipid-containing drops for evaporative dry eye (to replenish the lipid layer) and aqueous-based drops for aqueous deficiency. Step 2 (Mild to Moderate): If Step 1 is insufficient, add anti-inflammatory therapy — cyclosporine 0.05% (Restasis) or lifitegrast 5% (Xiidra) drops, which suppress the immune-mediated inflammation driving the dry eye cycle and improve tear production over weeks to months. For meibomian gland dysfunction: warm compresses (5 to 10 minutes daily to melt solidified meibum), lid hygiene with hypochlorous acid spray or diluted baby shampoo, oral omega-3 fatty acid supplements (flaxseed oil or fish oil — evidence supports reduced inflammation and improved meibum quality), and in-office treatments such as thermal pulsation (LipiFlow) or intense pulsed light (IPL) therapy for MGD. Step 3 (Moderate to Severe): Punctal plugs — small silicone or collagen plugs inserted into the tear drainage openings (puncta) to retain natural and artificial tears on the ocular surface longer. This is a simple, reversible, in-office procedure that can provide significant relief. Autologous serum eye drops — made from the patient's own blood serum, containing growth factors and nutrients that promote corneal epithelial healing — are used for severe dry eye not responsive to conventional therapies. Step 4 (Severe): For severe dry eye with persistent corneal epithelial defects: therapeutic bandage contact lenses, amniotic membrane grafts, or tarsorrhaphy (partial eyelid closure) may be required. Systemic anti-inflammatory or immunosuppressive therapy is indicated for associated autoimmune disease. Dr. Prabha customizes the treatment plan and follows up regularly to assess response and escalate or de-escalate therapy.
Can screen time cause or worsen dry eyes?
Yes, prolonged screen use (computer, laptop, tablet, smartphone) is one of the most common contributors to dry eye in the modern world — a condition termed computer vision syndrome or digital eye strain. Several mechanisms are involved: (1) Reduced blink rate — the normal blink rate of approximately 15 to 20 blinks per minute drops to as low as 5 to 7 blinks per minute during concentrated screen work. Blinking is essential for spreading the tear film evenly across the ocular surface and expressing meibum from the meibomian glands. With reduced blinking, the tear film breaks up, meibum stagnates in the glands, and the ocular surface is exposed to the air for longer, accelerating evaporation. (2) Incomplete blinking — even when screen users do blink, the blinks are often incomplete (the eyelids do not fully close), leaving the inferior cornea exposed. (3) Upward gaze — screens are often positioned too high, causing the eyes to open wider and exposing more ocular surface area to evaporation. (4) Reduced environmental humidity — air-conditioned offices have low humidity, further promoting tear evaporation. Practical solutions include: consciously practicing complete, frequent blinking, positioning the screen slightly below eye level (so you look down, which promotes a more relaxed eyelid position), using preservative-free artificial tears before and during prolonged screen sessions, following the 20-20-20 rule religiously, and using a desktop humidifier. Dr. Prabha provides personalized ergonomic and behavioral counseling for screen-related dry eye at Neurovision Clinic.
Is dry eye curable, or will I need treatment forever?
Dry eye is typically a chronic condition that requires ongoing management, much like hypertension or diabetes — the goal is to control symptoms, prevent progression, and protect the ocular surface from damage, rather than to achieve a one-time cure. However, the prognosis is excellent with appropriate treatment. Most patients achieve significant symptom relief within weeks to months of starting a tailored treatment regimen and can maintain comfort with a simplified maintenance routine. For evaporative dry eye due to meibomian gland dysfunction, improving gland function with warm compresses, lid hygiene, and omega-3 supplementation can restore a healthier tear film, and environmental modifications produce sustained benefit. For aqueous-deficient dry eye, anti-inflammatory therapy with cyclosporine or lifitegrast improves lacrimal gland function over time. Punctal plugs provide long-lasting benefit. The key is early intervention — untreated chronic dry eye can lead to corneal epithelial damage, sterile corneal ulcers, filamentary keratitis, and increased risk of bacterial keratitis. Dr. Dibya Prabha emphasizes that dry eye should not be accepted as something you just have to live with — effective treatments are available, and she works with each patient to find the combination that restores comfort and quality of life.